Getinge enters into commercial distribution agreement with Cook Medical for iCast covered stent system in the United States
Today, Getinge and Cook Medical announced an exclusive sales and distribution agreement for the iCast covered stent system, which has been on the market for twenty years and recently received premarket approval for treatment of iliac arterial occlusive disease.
The agreement includes a 60-day transition period after which Cook Medical will assume the sales, marketing and distribution rights for the product in the United States. The iCast covered stent system will continue to be manufactured by Getinge’s legal entity Atrium Medical Corporation in Merrimack, NH.
“This agreement with Cook Medical ensures that the iCast covered stent system will reach the optimal number of patients who will benefit from it in the United States,” said Patricia Fitch, President of Getinge NA. “This distribution agreement allows Getinge to best serve the U.S. market and accelerate our product innovation pipeline, in alignment with our global business strategy.”
“This product fills the need of a covered stent in our vascular portfolio with a proven technology. iCast has five-year data aligned with our commitment to long-term clinical evidence and predictable results for PAD therapies,” said Mark Breedlove, Senior Vice President of Cook Medical’s Vascular Division. “As Cook evolves to better meet customer needs, we are glad to work with other manufacturers to get products to physicians and patients faster. Our team is excited to support and distribute the iCast covered stent system across the U.S.”
The iCast covered stent system is an identical device to Getinge’s Advanta V12 covered stent system, which is sold outside the US and has been used by clinicians for two decades. Distribution outside of the US is not affected by this announcement.